系统性硬化症(systemic sclerosis,SSc)是一种病因未明,临床上以皮肤增厚或纤维化为特征,且可累及全身多器官的自身免疫性疾病;SSc可分为肢端型和弥漫型两类。SSc主要病理机制包括微血管病变、免疫功能失调导致针对多种细胞抗原的自身抗体产生和多脏器纤维化三个方面。SSc...
系统性硬化症(systemic sclerosis,SSc)是一类以皮肤和多脏器纤维化为特征表现的自身免疫病,间质性肺病(interstitial lung disease,ILD)是SSc的重要合并症,也是导致患者死亡的首要原因。对于系统性硬化症相关间质性肺病(SSc-ILD)的评估和管理『临床问答:系统性硬化症相关间质性肺病,你了解吗?』https://mp.weixin....
Systemic sclerosis (SSc)Systemic sclerosis (SSc), or: scleroderma, is a clinically heterogeneous, systemic disorder which affects the connective tissue of the skin, internal organs and the walls of blood vessels. It is characterized by alterations of the microvasculature, disturbances of the immune ...
系统性硬皮病(Systemic Sclerosis,SSc)是一种自身免疫性疾病,其严重程度因个体差异而异。疾病的严重程度可能受到多种因素的影响,包括病情类型、遗传因素、环境因素以及以下是系统性硬皮病可能对身体产生的影响:皮肤症状:系统性硬皮病最常见的症状是皮肤淋巴瘤和紧张,通常从手指破裂开始。皮肤可能变得僵硬、厚实,失...
Systemic sclerosis (SSc) is a rare systemic chronic disease characterized by widespread fibrosis of skin and internal organs, microvasculopathy, and autoantibodies that frequently affects internal organs and quality of life and survival. Disease-related autoantibodies, anti-topoisomerase I, anticentromere,...
系统性硬化症(systemic sclerosis SSc)是一种全身性结缔组织病。特点是胶原增生,炎症细胞浸润,血管阻塞,缺血性萎缩… www.medicchina.com|基于11个网页 2. 系统性硬皮病 系统性硬皮病(systemic sclerosis ssc)是一种以皮肤增厚和纤维化为特征的影响多个内脏系统的结缔组织疾病。具有谱性表现 … ...
Systemic Sclerosis(SSc) /Scleroderma ● Symptoms and Causes Scleroderma is an autoimmune disease of the connective tissue caused by increased production and accumulation of the protein collagen in the body tissues. Collagen overproduction could be influenced by: Abnormal immune reactions/Changes in genes...
and management of systemic sclerosis (SSc) remains challenging, owing to the complexity of this disease. In this Perspective, an international group of experts discuss the future of SSc research and how the advent of innovative technologies will advance research into and understanding of SSc. ...
Systemic sclerosis (SSc) is considered by many to be one of the most severe autoimmune rheumatic diseases with lower prevalence observed in Northern Europe. No previous studies on the prevalence of SSc in Latvia have been conducted and the aim was to study the demographic and clinical data of ...
The assessment of disease activity in systemic sclerosis (SSc) is challenging owing to its heterogeneous manifestations across multiple organ systems, the variable rate of disease progression and regression, and the relative paucity of patients in early-phase therapeutic trials. Despite some recent succes...